(NASDAQ: IBRX) Immunitybio's forecast annual revenue growth rate of 102.46% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 86.2%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Immunitybio's revenue in 2025 is $56,600,000.On average, 3 Wall Street analysts forecast IBRX's revenue for 2025 to be $96,806,368,055, with the lowest IBRX revenue forecast at $93,107,586,473, and the highest IBRX revenue forecast at $102,371,082,386. On average, 3 Wall Street analysts forecast IBRX's revenue for 2026 to be $209,036,456,805, with the lowest IBRX revenue forecast at $133,120,217,289, and the highest IBRX revenue forecast at $264,104,158,989.
In 2027, IBRX is forecast to generate $480,851,058,260 in revenue, with the lowest revenue forecast at $401,733,241,125 and the highest revenue forecast at $559,968,875,394.